Astellas' eye med Izervay lands key FDA label update, amping up market battle with Apellis rival
The geographic atrophy drug can now be dosed beyond a 12-month window, a prior label restriction that led many patients to pause treatment.
The geographic atrophy drug can now be dosed beyond a 12-month window, a prior label restriction that led many patients to pause treatment.
